160 related articles for article (PubMed ID: 36416910)
1. Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries.
Bessone F; Ferrari A; Hernandez N; Mendizabal M; Ridruejo E; Zerega A; Tanno F; Reggiardo MV; Vorobioff J; Tanno H; Arrese M; Nunes V; Tagle M; Medina-Caliz I; Robles-Diaz M; Niu H; Alvarez-Alvarez I; Stephens C; Lucena MI; Andrade RJ
Arch Toxicol; 2023 Feb; 97(2):593-602. PubMed ID: 36416910
[TBL] [Abstract][Full Text] [Related]
2. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries.
García-Cortés M; Ortega-Alonso A; Matilla-Cabello G; Medina-Cáliz I; Castiella A; Conde I; Bonilla-Toyos E; Pinazo-Bandera J; Hernández N; Tagle M; Nunes V; Parana R; Bessone F; Kaplowitz N; Lucena MI; Alvarez-Alvarez I; Robles-Díaz M; Andrade RJ
Liver Int; 2023 Aug; 43(8):1749-1760. PubMed ID: 37269163
[TBL] [Abstract][Full Text] [Related]
3. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
Chalasani N; Li YJ; Dellinger A; Navarro V; Bonkovsky H; Fontana RJ; Gu J; Barnhart H; Phillips E; Lammert C; Schwantes-An TH; Nicoletti P; Kleiner DE; Hoofnagle JH;
J Hepatol; 2023 Feb; 78(2):293-300. PubMed ID: 36152763
[TBL] [Abstract][Full Text] [Related]
4. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
Björnsson ES; Stephens C; Atallah E; Robles-Diaz M; Alvarez-Alvarez I; Gerbes A; Weber S; Stirnimann G; Kullak-Ublick G; Cortez-Pinto H; Grove JI; Lucena MI; Andrade RJ; Aithal GP
Liver Int; 2023 Jan; 43(1):115-126. PubMed ID: 35899490
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
Stephens C; Robles-Diaz M; Medina-Caliz I; Garcia-Cortes M; Ortega-Alonso A; Sanabria-Cabrera J; Gonzalez-Jimenez A; Alvarez-Alvarez I; Slim M; Jimenez-Perez M; Gonzalez-Grande R; Fernández MC; Casado M; Soriano G; Román E; Hallal H; Romero-Gomez M; Castiella A; Conde I; Prieto M; Moreno-Planas JM; Giraldez A; Moreno-Sanfiel JM; Kaplowitz N; Lucena MI; Andrade RJ;
J Hepatol; 2021 Jul; 75(1):86-97. PubMed ID: 33539847
[TBL] [Abstract][Full Text] [Related]
6. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury.
de Boer YS; Kosinski AS; Urban TJ; Zhao Z; Long N; Chalasani N; Kleiner DE; Hoofnagle JH;
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):103-112.e2. PubMed ID: 27311619
[TBL] [Abstract][Full Text] [Related]
7. Serious liver injury induced by Nimesulide: an international collaborative study.
Bessone F; Hernandez N; Mendizabal M; Ridruejo E; Gualano G; Fassio E; Peralta M; Fainboim H; Anders M; Tanno H; Tanno F; Parana R; Medina-Caliz I; Robles-Diaz M; Alvarez-Alvarez I; Niu H; Stephens C; Colombato L; Arrese M; Reggiardo MV; Ono SK; Carrilho F; Lucena MI; Andrade RJ
Arch Toxicol; 2021 Apr; 95(4):1475-1487. PubMed ID: 33759010
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver.
Bessone F; Hernandez N; Tagle M; Arrese M; Parana R; Méndez-Sánchez N; Ridruejo E; Mendizabal M; Dagher L; Contreras F; Fassio E; Pessoa M; Brahm J; Silva M
Ann Hepatol; 2021; 24():100321. PubMed ID: 33609753
[TBL] [Abstract][Full Text] [Related]
9. Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network.
Bessone F; García-Cortés M; Medina-Caliz I; Hernandez N; Parana R; Mendizabal M; Schinoni MI; Ridruejo E; Nunes V; Peralta M; Santos G; Anders M; Chiodi D; Tagle M; Montes P; Carrera E; Arrese M; Lizarzabal MI; Alvarez-Alvarez I; Caballano-Infantes E; Niu H; Pinazo J; Cabello MR; Lucena MI; Andrade RJ
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e548-e563. PubMed ID: 33434654
[TBL] [Abstract][Full Text] [Related]
10. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis.
Lucena MI; Kaplowitz N; Hallal H; Castiella A; García-Bengoechea M; Otazua P; Berenguer M; Fernandez MC; Planas R; Andrade RJ
J Hepatol; 2011 Oct; 55(4):820-7. PubMed ID: 21338638
[TBL] [Abstract][Full Text] [Related]
11. Relapse and Need for Extended Immunosuppression: Novel Features of Drug-Induced Autoimmune Hepatitis.
Weber S; Gerbes AL
Digestion; 2023; 104(3):243-248. PubMed ID: 36603570
[TBL] [Abstract][Full Text] [Related]
12. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
Chalasani N; Bonkovsky HL; Fontana R; Lee W; Stolz A; Talwalkar J; Reddy KR; Watkins PB; Navarro V; Barnhart H; Gu J; Serrano J;
Gastroenterology; 2015 Jun; 148(7):1340-52.e7. PubMed ID: 25754159
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial.
Wang JB; Huang A; Wang Y; Ji D; Liang QS; Zhao J; Zhou G; Liu S; Niu M; Sun Y; Tian H; Teng GJ; Chang BX; Bi JF; Peng XX; Xin S; Xie H; Ma X; Mao YM; Liangpunsakul S; Saxena R; Aithal GP; Xiao XH; Zhao J; Zou Z
Aliment Pharmacol Ther; 2022 May; 55(10):1297-1310. PubMed ID: 35362188
[TBL] [Abstract][Full Text] [Related]
14. Rechallenge in idiosyncratic drug-induced liver injury: An analysis of cases in two large prospective registries according to existing definitions.
Pinazo-Bandera JM; Niu H; Alvarez-Alvarez I; Medina-Cáliz I; Del Campo-Herrera E; Ortega-Alonso A; Robles-Díaz M; Hernández N; Paraná R; Nunes V; Girala M; Bessone F; Lucena MI; Andrade RJ; García Cortés M
Pharmacol Res; 2024 May; 203():107183. PubMed ID: 38631619
[TBL] [Abstract][Full Text] [Related]
15. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports.
Björnsson ES; Medina-Caliz I; Andrade RJ; Lucena MI
Hepatol Commun; 2022 Aug; 6(8):1895-1909. PubMed ID: 35596597
[TBL] [Abstract][Full Text] [Related]
16. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
Andrade RJ; Aithal GP; de Boer YS; Liberal R; Gerbes A; Regev A; Terziroli Beretta-Piccoli B; Schramm C; Kleiner DE; De Martin E; Kullak-Ublick GA; Stirnimann G; Devarbhavi H; Vierling JM; Manns MP; Sebode M; Londoño MC; Avigan M; Robles-Diaz M; García-Cortes M; Atallah E; Heneghan M; Chalasani N; Trivedi PJ; Hayashi PH; Taubert R; Fontana RJ; Weber S; Oo YH; Zen Y; Licata A; Lucena MI; Mieli-Vergani G; Vergani D; Björnsson ES;
J Hepatol; 2023 Sep; 79(3):853-866. PubMed ID: 37164270
[TBL] [Abstract][Full Text] [Related]
17. The progression of chronicity and autoimmune hepatitis in recurrent drug-induced liver injury.
He T; Ren L; Gong M; Guo Y; Wang L; Xiao X; Wang R; Bai Z
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102009. PubMed ID: 35977662
[TBL] [Abstract][Full Text] [Related]
18. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.
Björnsson ES; Bergmann OM; Björnsson HK; Kvaran RB; Olafsson S
Gastroenterology; 2013 Jun; 144(7):1419-25, 1425.e1-3; quiz e19-20. PubMed ID: 23419359
[TBL] [Abstract][Full Text] [Related]
19. Nitrofurantoin-induced hepatotoxicity: a rare yet serious complication.
Sakaan SA; Twilla JD; Usery JB; Winton JC; Self TH
South Med J; 2014 Feb; 107(2):107-13. PubMed ID: 24926677
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis due to nitrofurantoin.
Mollison LC; Angus P; Richards M; Jones RM; Ireton J
Med J Aust; 1992 Mar; 156(5):347-9. PubMed ID: 1588868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
